Sarepta Therapeutics Inc Update Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Heading into the study, you had guided potentially to see a 1.3 point difference based off a lot of the powering assumptions, what you would need to hit for static. So given that there were a number of trial updates and other factors that you made, can you talk about how each arm essentially performed relative to what your expectations were with these powering assumptions?

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : So first on time to horizon 10-minute walk, they seem to be trending better in the 6- to 7-year olds, which I think is contrary to what we've seen previously and what would be expected. Any comments on this? And then from a regulatory standpoint, I know this has been asked in the coming ways, but I just want to question this. Like what is your base case expectation? It sounds like it's full approval in 4 to 5, but I just wanted to confirm this. And then from a manufacturing perspective, what will you prepare for in terms of a market size? Will it be this 4- to 5-year old full approval or removal of an age restriction?

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : So on your FDA discussions to date, were there any different conversations on expanding the label to all ages versus expanding into all ambulation statuses? I'm just trying to get a sense if the FDA used both of these label expansion aspects together or if they may be separate considerations?